DarioHealth Corp Selected Fundamentals

DarioHealth Corp -- USA Stock  

USD 1.49  0.03  2.05%

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Current Ratio Analysis

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
DarioHealth Corp 
Current Ratio 
Current Asset 
Current Liabilities 
2.58 times
 DarioHealth Corp Current Ratio 

About Current Ratio

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e. Current Ration of 2 to 1).
Compare to competition


DarioHealth Corp Income Change Over Time

Consolidated Income

In accordance with recently published financial statements DarioHealth Corp has Current Ratio of 2.58 times. This is 11.34% lower than that of the Healthcare sector, and significantly higher than that of Medical Equipment industry, The Current Ratio for all stocks is 21.82% higher than the company.

DarioHealth Corp Fundamental Drivers Relationships

DarioHealth Corp is rated # 3 in current valuation category among related companies. It is rated # 3 in operating margin category among related companies .

Peer Comparison

DarioHealth Corp EBITDA Comparison
      DarioHealth Corp Comparables 
DarioHealth Corp is rated # 2 in ebitda category among related companies.

Did you try this?

Run Portfolio Backtesting Now

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
Hide  View All  NextLaunch Portfolio Backtesting